WO2022162513 - PHARMACEUTICAL COMPOSITION
National phase entry is expected:
Publication Number
WO/2022/162513
Publication Date
04.08.2022
International Application No.
PCT/IB2022/050578
International Filing Date
24.01.2022
Title **
[English]
PHARMACEUTICAL COMPOSITION
[French]
COMPOSITION PHARMACEUTIQUE
Applicants **
NOVARTIS AG
Lichtstrasse 35
4056 Basel, CH
Inventors
JUHNKE, Michael
Novartis Pharma AG
Postfach
4002 Basel, CH
RAPP, Karin
Novartis Pharma AG
Postfach
4002 Basel, CH
SIN, Kim-Hien
Novartis Pharma AG
Postfach
4002 Basel, CH
Priority Data
63/141,558
26.01.2021
US
63/240,438
03.09.2021
US
63/290,251
16.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1999 | |
| EPO | Filing, Examination | 7248 | |
| Japan | Filing | 593 | |
| South Korea | Filing | 640 | |
| USA | Filing, Examination | 3535 |
Total: 14015 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to the field of pharmacy, particularly to a pharmaceutical composition for oral administration comprising a pharmaceutical composition for oral administration comprising: (a) an inert substrate, and (b) a mixture comprising N-(3-(6-amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide, or a pharmaceutically acceptable salt thereof, or a free form thereof, and at least one binder. The present invention also relates to a process for preparing said pharmaceutical composition for oral administration; and to the use of said pharmaceutical composition in the manufacture of a medicament.[French]
La présente invention concerne le domaine de la pharmacie, en particulier une composition pharmaceutique pour administration orale comprenant : (a) un substrat inerte et (b) un mélange comprenant du N-(3-(6-amino-5-(2- (N-méthylacrylamido)éthoxy)pyrimidin-4-yl)-5-fluoro-2-méthylphényl)-4-cyclopropyl-2-fluorobenzamide ou un sel pharmaceutiquement acceptable correspondant, ou une forme libre correspondante et au moins un liant. La présente invention concerne également un procédé pour préparer ladite composition pharmaceutique destinée à une administration orale ; et l'utilisation de ladite composition pharmaceutique dans la fabrication d'un médicament.